Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

Combining gene therapy with stem cells leads to faster healing of burns

Johns Hopkins researchers, working with elderly mice, have determined that combining gene therapy with an extra boost of the same stem cells the body already uses to repair itself leads to faster healing of burns and greater blood flow to the site of the wound.

10 Oct 2013

Scientist develop novel system to monitor behavior of patients suffering from schizophrenia

Schizophrenia is a potentially debilitating mental illness affecting a person's thought processes, perception, language and sense of oneself.

19 Sep 2013

GW researcher awarded NEI grant to study developmental origins of wakefulness in cerebral cortex

Matthew Colonnese, Ph.D., assistant professor of pharmacology and physiology at the George Washington University School of Medicine and Health Sciences, was awarded a $1,973,645 grant from the National Eye Institute to study developmental origins of wakefulness in the cerebral cortex, the region of the brain responsible for cognition and perception.

18 Sep 2013

Overexpression of cytoglobin gene inhibits hypoxic injury to neuroblastoma cells

Cytoglobin is a temporary oxygen reservoir, which might provide a minimal, but continuous supply of intracellular oxygen during ischemic and anoxic conditions.

17 Sep 2013

Drug used in patients for cancer treatment has beneficial effects on diabetes

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular pathway - a series of interaction among proteins - involved in the development of diabetes. Furthermore, they have found that a drug already approved for use in humans can regulate the pathway.

16 Sep 2013

Chemists Find New Way To Put The Brakes On Cancer

...

10 Sep 2013

Blind mole-rats live underground in low-oxygen environments, are long-lived and resistant to cancer

Like naked mole-rats (Heterocephalus gaber), blind mole-rats (of the genus Spalax) live underground in low-oxygen environments, are long-lived and resistant to cancer. A new study demonstrates just how cancer-resistant Spalax are, and suggests that the adaptations that help these rodents survive in low-oxygen environments also play a role in their longevity and cancer resistance.

4 Sep 2013

BES procedure may prevent cell apoptosis in stem cell-based transplantation therapy

Researchers at the Beihang University School of Biological Science and Medical Engineering, led by Dr. Yubo Fan, have discovered that Biphasic Electrical stimulation (BES), a non-chemical procedure, may be used as a strategy for preventing cell apoptosis in stem cell-based transplantation therapy.

26 Aug 2013

Even in advanced stages total tumor size can have major impact on survival in lung cancer patients

For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumor size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages total tumor size can have a major impact on survival.

20 Aug 2013

Study suggests Braintone has neuroprotective effects on ischemia-induced brain damage

Recently, the importance of the neurovascular unit, which is comprised of neurons, endothelial cells and astrocytes, has received great attention in the field of stroke, because stroke affects not only neurons, but also astrocytes and microvessels.

17 Aug 2013

Study provides information that validates genetic basis of adaptation to high altitudes

Research led by scientists from the University of California, San Diego has decoded the genetic basis of chronic mountain sickness (CMS) or Monge's disease. Their study provides important information that validates the genetic basis of adaptation to high altitudes, and provides potential targets for CMS treatment.

16 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis.

31 Jul 2013

Study: Breathing oxygen during radiation therapy can delay tumor growth

A multidisciplinary team at UT Southwestern Medical Center has found that measuring the oxygenation of tumors can be a valuable tool in guiding radiation therapy, opening the door for personalized therapies that keep tumors in check with oxygen enhancement.

24 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Researchers discover reason behind failed anti-cancer therapy

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells.

24 Jun 2013

Researchers discover potential target for cancer-fighting drugs

As tumors grow, their centers are squeezed of oxygen. And so tumors must flip specific genetic switches to survive in these hypoxic environments.

10 Jun 2013